

**Supplementary Table 1.** Association of plasma immune checkpoint proteins at baseline with increased hepatic steatosis index (HSI>0) at the end of follow-up (~ 5 years after SVR) in HIV/HCV-coinfected patients.

Marker	Un-adjusted			Adjusted		
	AMR (95%CI)	p-value	q-value	aAMR (95%CI)	p-value	q-value
BTLA	2.05 (1.39–3.03)	<b>&lt;0.001</b>	<b>0.004</b>	1.75 (1.23–2.50)	<b>0.003</b>	<b>0.022</b>
CD137(4-1BB)	2.08 (1.42–3.05)	<b>&lt;0.001</b>	<b>0.004</b>	1.69 (1.15–2.48)	<b>0.009</b>	<b>0.032</b>
CD152(CTLA4)	1.49 (1.01–2.20)	<b>0.046</b>	0.065	1.35 (0.95–1.92)	0.098	0.171
CD27	1.00 (0.81–1.23)	0.974	0.974	1.00 (0.81–1.23)	0.974	0.974
CD28	1.36 (1.05–1.78)	<b>0.025</b>	<b>0.043</b>	1.15 (0.90–1.48)	0.262	0.334
CD80	2.62 (1.45–4.73)	<b>0.002</b>	<b>0.006</b>	1.81 (1.11–2.93)	<b>0.020</b>	<b>0.057</b>
GITR	3.60 (1.75–7.42)	<b>&lt;0.001</b>	<b>0.005</b>	2.30 (1.26–4.21)	<b>0.009</b>	<b>0.032</b>
HVEM	1.21 (0.95–1.53)	0.124	0.157	1.21 (0.95–1.53)	0.124	0.173
IDO	0.90 (0.50–1.61)	0.719	0.774	0.84 (0.46–1.55)	0.587	0.685
LAG-3	1.50 (1.14–1.97)	<b>0.006</b>	<b>0.011</b>	1.32 (1.03–1.69)	<b>0.035</b>	<b>0.081</b>
PD-1	1.95 (1.26–3.00)	<b>0.004</b>	<b>0.009</b>	1.46 (0.95–2.25)	0.092	0.171
PD-L1	1.36 (1.14–1.62)	<b>0.001</b>	<b>0.005</b>	1.34 (1.13–1.60)	<b>0.002</b>	<b>0.022</b>
PD-L2	1.31 (1.02–1.68)	<b>0.036</b>	0.056	1.21 (0.96–1.52)	0.116	0.173
TIM-3	1.04 (0.85–1.26)	0.713	0.774	1.02 (0.85–1.24)	0.802	0.864

**Statistics:** Data were calculated by Generalized Linear Models (GLM) with a gamma distribution (log-link). Multivariable models were adjusted by age, gender, BMI, HSI at baseline, liver stiffness measurement (LSM), HCV treatment (IFN-based therapy or DAAs), and time from baseline to follow-up time, previously selected by a stepwise method (forward) (see **Results Section**). The q-values represent p-values corrected for multiple testing using the False Discovery Rate (FDR). Significant differences are shown in bold.

**Abbreviations:** AMR, arithmetic mean ratio; aAMR, adjusted AMR; 95%CI, 95% of confidence interval; p, level of significance; q, corrected level of significance; BTLA, B and T lymphocyte attenuator; CD, cluster of differentiation; GITR, glucocorticoid-induced TNFR-related; HVEM, herpesvirus entry mediator; IDO, indoleamine 2,3-dioxygenase; LAG-3, lymphocyte activation gene-3; PD-1, programmed cell death protein 1; PD-L1, programmed death-ligand 1; PD-L2, programmed death-ligand 2; TIM-3, T-cell immunoglobulin and mucin-domain containing-3.